Holen Sie sich die Stockscreener-App
77.55
3.31%
2.57
Schlusskurs vom Vortag:
$74.98
Offen:
$74.99
24-Stunden-Volumen:
58,964
Relative Volume:
0.06
Marktkapitalisierung:
$6.20B
Einnahmen:
$58.89M
Nettoeinkommen (Verlust:
$-240.88M
KGV:
-25.02
EPS:
-3.1
Netto-Cashflow:
$-239.96M
1W Leistung:
+6.46%
1M Leistung:
-10.84%
6M Leistung:
+71.45%
1J Leistung:
+91.17%
1-Tages-Spanne:
$74.72
$77.64
1-Wochen-Bereich:
$69.08
$77.75
52-Wochen-Spanne:
$19.45
$103.00
Kymera Therapeutics Inc Stock (KYMR) Company Profile
Firmenname
Kymera Therapeutics Inc
Sektor
Branche
Telefon
857-285-5314
Adresse
500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN
Vergleichen Sie KYMR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KYMR
Kymera Therapeutics Inc
|
77.53 | 6.00B | 58.89M | -240.88M | -239.96M | -3.10 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.00 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
810.42 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
408.64 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
812.45 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
176.41 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Kymera Therapeutics Inc Stock (KYMR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-06 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2025-11-03 | Fortgesetzt | Guggenheim | Buy |
| 2025-10-24 | Bestätigt | B. Riley Securities | Buy |
| 2025-10-21 | Eingeleitet | Mizuho | Outperform |
| 2025-09-18 | Bestätigt | H.C. Wainwright | Buy |
| 2025-09-17 | Eingeleitet | Barclays | Overweight |
| 2025-09-16 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2025-07-30 | Fortgesetzt | B. Riley Securities | Buy |
| 2025-07-03 | Fortgesetzt | Morgan Stanley | Overweight |
| 2025-06-03 | Hochstufung | B. Riley Securities | Neutral → Buy |
| 2025-06-03 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2025-06-02 | Hochstufung | BofA Securities | Neutral → Buy |
| 2025-05-20 | Fortgesetzt | Stifel | Buy |
| 2025-03-13 | Eingeleitet | Citigroup | Buy |
| 2024-12-10 | Eingeleitet | BTIG Research | Buy |
| 2024-12-06 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2024-12-02 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-11-18 | Eingeleitet | Stephens | Overweight |
| 2024-09-09 | Fortgesetzt | Leerink Partners | Outperform |
| 2024-08-26 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2024-04-22 | Eingeleitet | Oppenheimer | Outperform |
| 2024-02-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-01-04 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2024-01-03 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-12-19 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-06-30 | Eingeleitet | Truist | Buy |
| 2023-05-05 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2022-12-06 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2022-11-08 | Eingeleitet | Raymond James | Mkt Perform |
| 2022-08-15 | Eingeleitet | Jefferies | Buy |
| 2022-08-03 | Eingeleitet | Goldman | Buy |
| 2022-07-20 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-04-28 | Eingeleitet | Credit Suisse | Outperform |
| 2022-03-10 | Eingeleitet | JP Morgan | Neutral |
| 2022-02-10 | Eingeleitet | Wells Fargo | Overweight |
| 2021-09-30 | Eingeleitet | B. Riley Securities | Neutral |
| 2021-09-30 | Eingeleitet | Stifel | Buy |
| 2021-09-10 | Herabstufung | BofA Securities | Buy → Neutral |
| 2021-05-21 | Eingeleitet | UBS | Buy |
| 2021-04-14 | Eingeleitet | Berenberg | Buy |
| 2020-12-04 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-09-15 | Eingeleitet | BofA Securities | Neutral |
| 2020-09-15 | Eingeleitet | Cowen | Outperform |
| 2020-09-15 | Eingeleitet | Guggenheim | Buy |
| 2020-09-15 | Eingeleitet | Morgan Stanley | Equal-Weight |
Alle ansehen
Kymera Therapeutics Inc Aktie (KYMR) Neueste Nachrichten
Why Kymera Therapeutics Inc. stock is trending among retail traders2025 Price Momentum & AI Powered Buy/Sell Recommendations - ulpravda.ru
Why Kymera Therapeutics Inc. stock could see breakout soonJuly 2025 Selloffs & Weekly Consistent Profit Watchlists - ulpravda.ru
Will Kymera Therapeutics Inc. stock maintain growth storyWeekly Trade Report & Step-by-Step Trade Execution Guides - ulpravda.ru
Kymera Therapeutics (NASDAQ:KYMR) Nasdaq Composite ETF Protein Regulation - Kalkine Media
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat
Is Kymera Therapeutics (KYMR) Balancing Pipeline Ambition and Execution Risk After New KT-621 Milestone? - Yahoo Finance
Kymera Advances KT-621 Into Mid-Stage Asthma Trial, Setting Up a New Catalyst for KYMR Investors - TipRanks
Kymera jumps on early-stage data for eczema candidate KT-621 - MSN
Kymera Therapeutics, Inc. (KYMR) Stock Analysis: A Biotech Leader with a 59.70% Potential Upside - DirectorsTalk Interviews
Kymera Therapeutics (KYMR) Downgraded by Wolfe Research | KYMR S - GuruFocus
Kymera Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13 - The Manila Times
Kymera Therapeutics CEO to unveil 2026 milestones at JPMorgan event - Traders Union
Wolfe Research downgrades Kymera Therapeutics stock rating on lack of catalysts - Investing.com UK
KYMR Skyrockets 82.4% in a Year: More Upside Potential in 2026? - sharewise.com
Kymera Therapeutics stock extends slide as KYMR closes down 6.5% — what investors watch next - TechStock²
Kymera Therapeutics (KYMR) stock drops 6.6% to start 2026 as insider sale filing stays in focus - ts2.tech
KYMR Stock Falls -14% With A 7-day Losing Spree On Significant Insider Selling - Trefis
Kymera Therapeutics stock slides nearly 7% after CEO share-sale filing — what KYMR investors watch next - ts2.tech
Kymera Therapeutics (NASDAQ:KYMR) Trading Down 4.3%What's Next? - MarketBeat
Insider Buying: Smart Money Just Spent +$100M on These 3 Stocks - Investing.com
Kymera Therapeutics (KYMR) Sees 4% Drop in Stock Price - GuruFocus
Insider Buying: Smart Money Just Spent +$100M on These 3 Stocks - MarketBeat
The Technical Signals Behind (KYMR) That Institutions Follow - Stock Traders Daily
Kymera Therapeutics (NASDAQ:KYMR) CEO Nello Mainolfi Sells 30,000 Shares - MarketBeat
Kymera Therapeutics Insider Sold Shares Worth $2,341,939, According to a Recent SEC Filing - marketscreener.com
Kymera Therapeutics (NASDAQ: KYMR) CEO reports option exercise and share sale - Stock Titan
Kymera Therapeutics Earnings Notes - Trefis
Kymera Therapeutics (KYMR) stock falls today as biotech slips — what traders are watching - ts2.tech
Kymera Therapeutics announces results from BroADen Phase 1b trial of KT-621 - MSN
Citi Raises Kymera (KYMR) Price Target After Positive Drug Data, Keeps Buy Rating - MSN
Kymera draws upgrades after early-stage data for anti-inflammatory agent - MSN
B. Riley Securities Maintains Kymera Therapeutics (KYMR) Buy Recommendation - Nasdaq
Why Kymera Therapeutics Stock Is Sliding Despite Hype - TipRanks
KYMR: B. Riley Securities Raises Price Target for Kymera Therape - GuruFocus
B. Riley Raises Price Target on Kymera Therapeutics to $117 From $80, Keeps Buy Rating - marketscreener.com
Can Kymera Therapeutics Inc. stock hit analyst price targets2025 Valuation Update & Daily Growth Stock Tips - Улправда
Squarepoint Ops LLC Cuts Position in Kymera Therapeutics, Inc. $KYMR - MarketBeat
What momentum indicators show for Kymera Therapeutics Inc. stockDividend Hike & Low Risk Entry Point Guides - ulpravda.ru
Kymera Therapeutics (NASDAQ:KYMR) Shares Down 3.4%Here's What Happened - MarketBeat
Can Kymera Therapeutics Inc. stock deliver consistent earnings growth - Улправда
Kymera Therapeutics Insider Sold Shares Worth $2,264,480, According to a Recent SEC Filing - marketscreener.com
Share Offerings Prompt Huge Insider Buying in These 3 Biotechs - 24/7 Wall St.
Why Analysts See Kymera Therapeutics Differently After KT 621 Momentum And Rising Fair Value - Yahoo Finance
RBC Capital Maintains Kymera Therapeutics (KYMR) Outperform Recommendation - Nasdaq
Kymera Poised to Become Leading Firm in Multiple Inflammation & Immunology Indications, RBC Says - marketscreener.com
RBC Capital Raises Price Target for Kymera Therapeutics (KYMR) | - GuruFocus
RBC Raises Price Target on Kymera Therapeutics to $103 From $70, Keeps Outperform, Speculative Risk - marketscreener.com
Kymera Therapeutics stock price target raised to $103 from $70 at RBC Capital - Investing.com Canada
Kymera's eczema drug gets fast track designation in the United States - MSN
Obesity data, Kymera and FDA sentiment survey results — a BioCentury podcast - BioCentury
Kymera gains fast track status for oral candidate KT-621 for eczema - MSN
Finanzdaten der Kymera Therapeutics Inc-Aktie (KYMR)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.59%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):